Acute aluminium phosphide poisoning, what is new?
Singh Yatendra, Joshi Subhash C., Satyawali Vivekanand, Gupta Abhisek

Introduction
Aluminium phosphide (AlP) is a cheap solid fumigant and a highly toxic pesticide that is commonly used for grain preservation. AlP has currently generated interest with increasing number of cases in the past four decades because of its increased use for agricultural and nonagricultural purposes, and also its ease availability in the markets has led to its increased misuse to commit suicide. Ingestion is usually suicidal in intent, uncommonly accidental and rarely homicidal. The poison affects all systems, shock, cardiac arrhythmias with varied ECG changes and gastrointestinal features being the most prominent. Diagnosis is made on the basis of clinical suspicion, a positive silver nitrate paper test to phosphine, and gastric aspirate and visceral biochemistry. Treatment includes early gastric lavage with potassium permanganate or a combination of coconut oil and sodium bicarbonate, administration of charcoal and palliative care. Specific therapy includes intravenous magnesium sulphate and oral coconut oil. Unfortunately, the lack of a specific antidote results in very high mortality and the key to treatment lies in rapid decontamination and institution of resuscitative measures. This article aims to identify the salient features and mechanism of AlP poisoning along with its management strategies and prognostic variables.

Keywords:
aluminium phosphide, management, phosphine, poisoning, shock

Acute aluminium phosphide poisoning, what is new?
Singh Yatendra, Joshi Subhash C., Satyawali Vivekanand, Gupta Abhisek

Introduction
Aluminium phosphide (AlP) is a solid fumigant that has been used extensively since the 1940s. It is easily available and can be purchased in some countries such as India under the trade names, for example Celphos, Quickphos, Synfume and Phosfume [1]. AlP is a solid pesticide that rapidly became one of the most commonly used grain fumigants because of its properties, which are considered to be near ideal; it is toxic to all stages of insects, highly potent, does not affect seed viability, is free from toxic residues and leaves little residue on food grains [2]. This highly toxic chemical is cheap and usually formulated in tablets or pellets, granules and as dust. Upon contact with moisture in the environment, it undergoes a chemical reaction, yielding phosphine gas, which is the active pesticidal component [3].

No reports are available in the English literature from any part of the world where AlP has been ingested as a poison to commit suicide, except in Morocco (1995), where death rates by suicides by self administration of AlP pills are high [4], and in Denmark (1996), where a case of AlP ingestion has been reported. During the last two decades, poisoning because of AlP ingestion has been reported [5] widely from different Northern States of India, where the AlP poisoning was unknown before 1980. The first case was reported in 1981, but since then, the number of cases has been increasing progressively throughout North India so much so that it is now the single most common suicidal method and the problem has acquired an epidemic proportion [6–8]. It has currently generated interest with increasing number of cases in the past four decades because of its increased use for agricultural and nonagricultural purposes; also, its ease of availability has led to its increased misuse to commit suicide [9,10].

Aluminium phosphide
AlP is a solid fumigant and ideal pesticide since 1940 as it is cheap, most efficacious and easy to use and freely available over the counter in India (as Alphos, Celphos, Quickphos, Phostex, Phosfume and Synfume) and in Morocco (as Phostoxin) in the form of chalky white or brown 3 g tablets containing 56% of AlP and 44% of ammonium carbonate [4,11,12]. The tablets are taken out of a sealed container and placed on stored grains and the storage container is closed for a few days to eliminate moles and vermines in granaries [4]. AlP has a relatively high vapour pressure, which allows it to penetrate porous material effectively. On coming into contact with water or moisture or OH radical of air or hydrochloric acid in the stomach, a 3 g tablet of AlP releases 1 g of phosphine or phosphorus hydrogen [12], that is–

\[
\text{AlP + 3HCl = AlCl + PH}_3.
\]

Phosphine (PH₃)
PH is a colourless gas with a fishy or garlic odour with an odour threshold of 0.14 ppm and a vapour density
The Egyptian Society of Internal Medicine

It has a half-life of 5–24 h, which is dependent on the surface and the permeability of the solid matrix. The nontoxic residues, that is phosphites and hypophosphites of aluminium left in the grains, are less than 0.1 mg. PH (1 kg), for raw cereals, is the WHO-recommended permissible level considered safe for human consumption [12].

**Mechanism of action**

After oral intake, the phosphine gas released is absorbed by the gastrointestinal tract by simple diffusion. Phosphine, like cyanide, inhibits mitochondrial cytochrome oxidase and cellular oxygen utilization. Phosphine can inhibit cytochrome C oxidase *in vitro*, but it has much less activity *in vivo* [15–18]. This inhibits oxidative respiration by 70% and ultimately results in a marked decrease in mitochondrial membrane potential [16].

In the presence of AIP, cellular superoxide and peroxide radicals are generated, with subsequent cellular damage by lipid peroxidation [19–22]. The higher levels of superoxide dismutase, malondialdehyde and catalase in postmortem studies and decrease in the serum levels of these biochemical parameters to a normal level in survivors indicate their role in poisoning [23]. Some experimental results suggest the beneficial role of glutathione, melatonin, vitamin C and carotenes [24].

The direct toxic effects of phosphine on cardiac myocytes, fluid loss and adrenal gland can induce profound circulatory collapse [18]. Phosphides and phosphine can exert a direct corrosive effect on body tissues [25].

**Toxicity**

The fatal dose in an adult is 150–500 mg [10,26]. The permissible exposure limit is 0.3 ppm over an 8 h shift (for factory staff) [27].

**Epidemiology**

In the largest series comprising of 418 cases reported from Rohtak, India, the hospital incidence of AIP poisoning was 0.06/1 000 hospital admissions, which increased progressively to 10/1000 in 1989–1990, with a male female ratio of 2 : 1, and is now increasing continuously so as to surpass any other poisoning in Haryana [6,7]. In Washington State, AIP poisoning comprised 38.42% (15 out of 39 cases) of fumigant-related illnesses [14]. Stray incidences of AIP ingestion have been reported from Morocco and Denmark [4,5].

AIP poisoning is more common in the rural belt of North India, where the agricultural community, irrespective of sex, is more at risk, which correlates positively with illiteracy, frustration, depression, failure in examination, disputes in the family, inability to find suitable avenues of income and easy availability of AIP in the household [8,28]. The occupational threshold value of pH is 0.3 ppm [14] and a concentration of more than 7 ppm in air can cause serious illness; a concentration of 290–300 ppm is life threatening; 400–600 ppm is lethal in half an hour; and a concentration of 1000 ppm is rapidly fatal. The fatal dose after ingestion is 150 mg for a person weighing 70 kg and the fatal period is 1–96 h, the average being 28 h [6–8].

**Clinical manifestations**

Vomiting, abdominal pain, loose motions and restlessness are frequent presenting complaints. Cardiovascular involvement results in thready pulse, tachycardia, tachypnoea, acidosis, marked hypotension, palpitation and ultimately unresponsive shock. Patients remain mentally lucid until cerebral anoxia because of shock develops. AIP poisoning may have complications such as haemorrhage, acute renal failure, disseminated intravascular coagulation and arrhythmias. Several ECG changes ranging from ST segment elevation/depression, PR and QRS interval prolongation, complete heart block to ectopic pace making and also fibrillation have been reported [29].

Patients can present with anteroinferior wall ischaemia, right bundle branch block and T-wave flattening/inversion simulating myocardial ischaemia. These changes are because of toxic injury to myocardium [30]. Pulmonary oedema, dyspnoea, cyanosis and altered sensorium may be present in AIP poisoning. Other rare effects include hepatitis, disseminated intravascular coagulation and acute tubular necrosis [26,31].

**Laboratory investigations**

Laboratory evaluation is mainly performed to assess the prognosis. Leucopenia indicates severe toxicity. Increased SGOT or SGPT and metabolic acidosis indicate moderate to severe ingestional poisoning. Electrolyte analysis shows decreased magnesium, whereas potassium may be increased or decreased [32].

Measurement of plasma renin is significant as its level in blood has a direct relationship with mortality and is increased in direct proportion to the dose of pesticide. The serum level of cortisol is usually found to be decreased in severe poisoning [33]. Chest radiograph may indicate hilar or perihilar congestion if acute respiratory distress syndrome (ARDS) develops.

ECG shows various manifestations of cardiac injury (ST depression or elevation, bundle branch block, ventricular tachycardia, ventricular fibrillation)
Diagnosis
Diagnosis is made on the basis of clinical suspicion, history of inhalation exposure or history of ingestion of AIP, corroborated by seeing the tablets of AIP or its empty container left in the house, clinical manifestations with garlic or decaying fish odour, unexplained shock, a positive AgNO₃ test, chemical analysis of gastric juice and viscera and histopathological changes [37–39].

Mortality
The specified fatal dose of AIP is 0.15–0.5 g. However, most of the patients present with ingestion of three or more tablets, which invariably results in death [2]. The average time interval between ingestion of AIP and death is 3 h (1–48 h), 95% of the patients die within 24 h and the most common cause of death in this group is cardiac dysrhythmia. The severity of poisoning depends on the type of compound consumed. Fresh and active compounds (tablets) commonly affect the heart, lungs, gastrointestinal tract and kidneys, causing severe metabolic acidosis and high mortality. Broken or granular forms of tablets cause mild hypotension and ECG changes, mild metabolic acidosis and low mortality as the activity of the compound is less. The powder form of tablets is inactive, and causes no systemic effects and no mortality [40]. Death after 24 h occurs usually because of shock, acidosis, ARDS and cardiac dysrhythmia. Mortality depends on the dose of poison, severity of poisoning, duration of shock, failure of response of shock to resuscitative measures and severity of hypomagnesaemia [41]. Nonsurvivors have more severe hypotension and metabolic acidosis than the survivors who have more severe vomiting [31]. The mortality rate is highly variable, ranging from 37 to 100%, and can reach more than 60% even in experienced and well-equipped hospitals [2].

Management

General
The management of AIP poisoning should be initiated as soon as possible and should not be delayed on confirmation of poisoning [42]. Gastric lavage is performed with potassium permanganate (1 : 10 000) to reduce the absorption of phosphine. Potassium permanganate (1 : 10 000) oxidizes PH₃ to form nontoxic phosphate. This is followed by activated charcoal (~100 g) administered through a nasogastric tube. Antacids and proton pump blockers are added for symptomatic relief [43,44]. It is reported that lavage with coconut oil also plays a role in the management of acute AIP poisoning even 6 h after ingestion. Correction of plasma glucose levels may be useful in patient management [45,46].

The most important aspect is resuscitation of shock. An intravenous line should be established as soon as the patient arrives and 2–3 l of normal saline should be administered in the initial hours (8–12) guided by central venous pressure and pulmonary capillary wedge pressure. The aim is to maintain the central venous pressure at around 12–14 cm of water [47]. Some reports have recommended rapid infusion of saline (3–6 l) in the initial 3 h. Low-dose dopamine (4–6 µg/kg/min) is administered to maintain systolic blood pressure greater than 90 mmHg. Hydrocortisone 200–400 mg every 4–6 h is administered intravenously to combat shock, reduce the dose of dopamine, check capillary leakage in lungs (ARDS) and to potentiate the responsiveness of the body to endogenous and exogenous catecholamines [24,48,49]. Oxygen is administered for hypoxia. Phosphine excretion can be increased by maintaining adequate hydration and renal perfusion with intravenous fluids and low-dose dopamine (4–6 µg/kg/min). Diuretics such as furosemide can be administered if systolic blood pressure is greater than 90 mmHg to enhance the excretion of phosphine [50]. All types of ventricular arrhythmias can be observed in these patients and the management is the same as for arrhythmias in other situations [50]. Bicarbonate level less than 15 mEq/l requires sodabicarb at a dose of 50–100 mEq intravenously every 8 h until the bicarbonate level increases to 18–20 mEq/l [36].

Specific therapy
There is no specific therapy for this poisoning. The management of intoxication from AIP is mainly supportive. The administration of H₂ receptor antagonists or proton pump inhibitors has been recommended to reduce the gastric acidity and further release of phosphine gas. Hypomagnesaemia is a common outcome of phosphine gas exposure and intracellular magnesium plays an important role as a cofactor in the synthesis of several antioxidants; thus, administration of intravenous magnesium has been investigated in cases of AIP poisoning [51].

In a trial of 50 patients, individuals receiving repeated doses of intravenous magnesium showed significant improvement in indicators of oxidative stress and a lower incidence of mortality (20%) in comparison with control participants (44% mortality) [52]. Oral administration of the anti-ischaemic drug trimetazidine, which
works through a metabolic mechanism of decreasing the production of oxygen-derived free radicals and stimulating the oxidative metabolism of glucose, has been suggested. It was temporally associated with clinical improvement in a case report of occupational inhalation exposure to phosphine gas from AIP [53–55]. The use of magnesium sulphate (both high and low dose) did not improve survival in controlled clinical trials. Hence, its use is not recommended [56]. Administration of sorbitol solution (at a dose of 1–2 ml/kg) as a cathartic and vegetable oils and liquid paraffin as an inhibitor of phosphine release from the overdosed AIP has been suggested [57]. Digoxin has been suggested for the treatment of cardiogenic shock induced by acute AIP intoxication [58].

Conclusion
Exposure to phosphine gas released from AIP fumigants increases the risk of major morbidity and mortality. There is an increasing need for improved knowledge of these risks, with an emphasis on recognition, management and prevention.

The mortality because of AIP poisoning is very high and variable, and depends on a number of factors, the lack of an antidote and the poor prognostic signs being the most prominent. The use of MgSO4 to reduce cardiac arrhythmias and mortality, is well documented and recommended. The fast progression to life-threatening symptoms, ineffective therapeutic ways to counter its intoxication and limited data on the efficacy of therapeutic interventions pose challenges to the clinicians and emergency staff.

The most important factor that may help to improve survival is providing preliminary medical aid within 0.5–1 h of AIP intake at grassroot levels. Other preventive measures could be the caging of tablets in plastic packs with holes and spikes and more stringent restrictions on its supply in open market. The applicators of AIP must be licensed or should work under the supervision of a licensed individual. Improved education and enforcement of safety regulations would help to reduce the frequency of the illness. Thus, the problem needs to be tackled by using a multifaceted approach in the form of preventive measures, updating the management modalities at all levels and overall, study of and research for an antidote that can prevent further loss of human lives as a result of poisoning.

Acknowledgements
Conflicts of interest
There are no conflicts of interest.

References
1 Chopra JS, Kaipa OP, Malik VS, Sharma R, Chandra A. Aluminium phosphide poisoning: a prospective study of 16 cases in one year. Postgrad Med J 1986; 62:1113–1115.
2 Wahab A, Rabbani MU, Wahab S, Khan RA. Spontaneous self-ignition in a case of acute aluminium phosphide poisoning. Am J Emerg Med 2009; 27:752–756.
3 Sudakin DL. Occupational exposure to aluminium phosphide and phosphine gas? A suspected case report and review of the literature. Hum Exp Toxicol; 2005; 24:27–33.
4 Ictai B, Miguil M, Moutawakkil S, Bouagadag A, Guerirt A, Abbassi O, Ben Aguida M. Acute phostoxin poisoning. Presse Med 1995; 24:611–612.
5 Anderson TS, Horn JW. Poisoning with aluminium phosphide used as a poison against moles. Ugeskr Laeger 1996; 158:308–309.
6 Bajaj R, Wasir BS, et al. Epidemiology of AIP poisoning. Need for a survey. J Assoc Physicians India 1990; 30:197–198.
7 Chugh SN, DS Ram, Arora B, et al. Incidence and outcome of AIP poisoning in a hospital study. Indian J Med Res 1992; 94:232–235.
8 Siwach SB, Yadav DR, Arora B, et al. Acute aluminium phosphide poisoning. An Epidemiological, Clinical and Histopathological study. J Assoc Physicians India 1988; 36:594–596.
9 Bajpai SR. Aluminium phosphide poisoning: management and prevention. J Indian Acad Forensic Med 2010; 32:352–354.
10 Ferrer MI, Alvarez LF, Cepero RA, et al. Suicide by ingestion of aluminium phosphide: a case report. Emergencias 2009; 21:228–231.
11 Singh S, Singh O, Wig N, Jit I, Sharma BK. Aluminium phosphide ingestion: A clinico-pathological study. J Toxicol Clin Toxicol 1996; 34:703–706.
12 Chugh SN, et al. Aluminium phosphide poisoning present status and management. An update. J Assoc Physicians India 1992; 40:401–405.
13 National Occupational Hazard Survey Publication (NIOCH). U.S. Department of Health Education and Welfare, 1977
14 Burgess JL, Mossissey B, Kefler MC, Robertson Wo. Fumigant related illness, Washington State’s five year experience. J Toxicol Clin Toxicol 2000; 38:7–14.
15 Rigobello MP, Scutari G, Boscolo R, Bindoll A. Induction of mitochondrial permeability transition by auranofin, a gold(III)phosphine derivative. Br J Pharmacol 2002; 136:1162–1168.
16 Valmas N, Zuryn S, Ebert PR. Mitochondrial uncouplers act synergistically with the fumigant phosphine to disrupt mitochondrial membrane potential and cause cell death. Toxicology 2008; 252:33–39.
17 Wang W, Winther JR, Thorpe C. Erv2p: characterization of the redox behavior of a yeast sulfhydryl oxidase. Biochemistry 2007; 46:3246–3254.
18 Proudfoot AT. Aluminium and zinc phosphide poisoning. Clin Toxicol (Phila) 2009; 47:89–100.
19 Almassieh M, Lieven CJ, Levin LA, Di Polo A. A cell-permeable phosphineborane complex delays retinal ganglion cell death after axonal injury through activation of the pro-survival extracellular signal-regulated kinases 1/2 pathway. J Neurochem 2011; 118:1075–1086.
20 Hsu CH, Quistad GB, Casida JE. Phosphate-induced oxidative stress in Hepa 1c17 cells. Toxicol Sci 1998; 46:204–210.
21 Lieven CJ, Levin LA. Tools for studying early events in optic neuropathies. Eye (Lond) 2007; 21:S21–S24.
22 Nguyen SM, Alexejun CN, Levin LA. Amplification of a reactive oxygen species signal in axotomized retinal ganglion cells. Antioxid Redox Signal 2003; 5:629–634.
23 Chugh SN, Arora V, Sharma A, Chugh K. Free radical scavengers & lipid peroxidation in acute aluminium phosphide poisoning. Indian J Med Res 1996; 104:190–193.
24 Shadnia S, Soltaninejad K. Spontaneous ignition due to intentional acute aluminium phosphide poisoning. J Emerg Med 2009; 40:179–181.
25 Glindeemann D, Eismann F, Bergmann A, Kusch P, Strotmeyer U. Phosphine by bio-corrosion of phosphide-rich iron. Environ Sci Pollut Res Int 1998; 5:71–74.
26 Ranga GS, Dwivedi S, Agarwal M, Kumar D. Aluminium phosphide poisoning in a young adult: a suicidal cardiotoxin simulating myocardial ischaemia. J Indian Acad Clin Med 2004; 5:369.
27 Mittra S, Peshin SS, Lal SB. Cholinesterase inhibition by aluminium phosphide poisoning in rats and effects of atropine and pralidoxime chloride. Acta Pharmacol Sin 2001; 22:37–39.
28 SB Siwach A Gupta. The profile of acute poisoning in Haryana-Rohtak study. J Assoc Physicians India 1995; II:756–779.
Aluminium phosphide poisoning

Singh et al.

29 Katira R, Elhence GP, Mehrotra ML, Srivastava SS, Mitra A, Agarwala R. et al. A study of aluminum phosphide (AlP) poisoning with special reference to electrocardiographic changes. J Assoc Physicians India 1990; 38:471–473.

30 Mathur A, Swaroop A, Aggarwal A. ECG changes in aluminium phosphide and organo phosphorus poisoning. Indian Practitioner 1999; 52:249–252.

31 Singh S, Singh D, Wig N, Jit I, Sharma BK. Aluminium phosphide ingestion — a clinicopathologic study. J Toxicol Clin Toxicol 1996; 34:703–706.

32 Chugh SN, Juggal KL, Sharma A, Arora B, Malhotra KC. Magnesium levels in aluminium phosphide poisoning [abstract]. J Assoc Physicians India 1990; 38:32.

33 Chugh SN, Ram S, Sharma A, Arora BB, Sani AS, Malhotra KC. Adrenocortical involvement in aluminium phosphide poisoning. Indian J Med Res 1989; 90:289–294.

34 Jain SM, Bharani A, Sepaha GC, Sanghvi VC, Raman PG. Electrocardiographic changes in aluminium phosphide (ALP) poisoning [case reports]. J Assoc Physicians India 1985; 33:406–409.

35 Siwach SB, Singh H, Jagdish, Katyal VK, Bhardwaj G. Cardiac arrhythmias in aluminium phosphide poisoning studied by continuous holter and cardioscopic monitoring. J Assoc Physicians India 1998; 46:596–601.

36 Singh RB, Rastogi SS, Singh DS. Cardiovascular manifestations of aluminium phosphide intoxication. J Assoc Physicians India 1989; 37:590–592.

37 Chugh SN, Chugh K, S Ram, et al. Spot diagnosis of aluminium phosphide ingestion. An application of simple test. J Assoc Physicians India 1989; 37:219.

38 Arora B Punia RS Kalara R, Chugh SN, Arora DR. Histopathological changes in aluminium phosphide poisoning. J Indian Med Assoc 1995; 93:360–361.

39 Singh S Wig N Chowdhary D Sood NK Sharma BK. Changing pattern of acute poisoning in adults experience of a large North West Indian Hospital (1970–1989). J Assoc Physicians India 1997; 3:194–197.

40 Chugh SN, Arora V, Kaur S, Sood AK. Toxicty of exposed aluminium phosphide. J Assoc Physicians India 1993; 41:569–570.

41 Chugh SN, Chugh K, Ram S, Malhotra KC. Electrocardiographic abnormalities in aluminium phosphide poisoning with special reference to its incidence, pathogenesis, mortality and histopathology. J Indian Med Assoc 1991; 89:32–35.

42 Gujjar M, Baronia AK, Azim A, Sharma K. Managing aluminum phosphate poisonings. J Emerg Trauma Shock 2011; 4:378–384.

43 Chugh SN, Mittal A, Seth S, Chugh K. Lipid peroxidation in acute aluminium phosphide poisoning. J Assoc Physicians India 1995; 43:265–266.

44 Grover A, Bansal S. Aluminium phosphide poisoning. Manual of medical emergencies. New Delhi: M M Healthcare; 1997.

45 Shadnia S, Mehrpour O, Abdullahi M. Unintentional poisoning by phosphine released from aluminium phosphide. Hum Exp Toxicol 2008; 27:87–89.

46 Shadnia S, Rahimi M, Pajoumand A, Rasouli MH, Abdullahi M. Successful treatment of acute aluminium phosphide poisoning: possible benefit of coconut oil. Hum Exp Toxicol 2005; 24:215–218.

47 Siwach SB, Jagdish K, Katyal VK, Dhall A, Bhardwaj G. Prognostic indices in aluminium phosphide poisoning observations on acidity & central venous pressure. J Assoc Physicians India 1997; 45:693–695.

48 Soltaninejad K, Faryadi M, Sardari F. Acute pesticide poisoning related deaths in Tehran during the period 2003–2004. J Forensic Leg Med 2007; 14:352–354.

49 Kondo S, Tokuhashi K, Nagai H, Iwasaka M, Kaise M. Spontaneous ignition limits of silane and phosphine. Combustion Flame 1995; 101:170–174.

50 International Programme on Chemical Safety. Environmental health criteria 73: phosphine and selected metal phosphides. Geneva: World Health Organization; 1998.

51 Chugh SN, Kumar P, Aggarwai HK, Sharma A, Mahajan SK, Malhotra KC. Efficacy of magnesium sulphate in aluminium phosphide poisoning — comparison of two different dose schedules. J Assoc Physicians India 1994; 42:373–375.

52 Chugh SN, Kolley T, Kakkar R, Chugh K, Sharma A. A critical evaluation of anti-peroxidant effect of intravenous magnesium in acute aluminium phosphide poisoning. Magnes Res 1997; 10:225–230.

53 de Leiris J, Boucher F. Rationale for trimetazidine administration in myocardial ischaemia-reperfusion syndrome. Eur Heart J 1993; Suppl G:34–40.

54 Lopaschuk GD. Treating ischemic heart disease by pharmacologically improving cardiac energy metabolism. Am J Cardiol 1998; 82:14K–17K.

55 Duenas A, Perez-Castilllon JL, Cobos MA, Herreros V. Treatment of the cardiovascular manifestations of phosphine poisoning with trimetazidine, a new antischismic drug. Am J Emerg Med 1999; 17:219–220.

56 Siwach SB, Singh P, Ahlawat S, Dua A, Sharma D. Magnesium & tissue magnesium content in patients of aluminium phosphide poisoning and critical evaluation of high dose magnesium sulphate therapy in reducing mortality. J Assoc Physicians India 1994; 42:107–110.

57 Goswami M, Bindal M, Sen P, Gupta SK, Avasthi R, Ram BK. Fat and oil inhibit phosphine release from aluminium phosphide-its clinical implication. Indian J Exp Biol 1994; 32:647–649.

58 Mehrpour O, Farzaneh E, Abdullahi M. Successful treatment of aluminum phosphide poisoning with digoxin: a case report and review of literature. Int J Pharmacol 2011; 7:761–764.